Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Phase I/II Study of Cediranib and Olaparib in Combination for Treatment of Recurrent Papillary-Serous Ovarian, Fallopian Tube, or Peritoneal Cancer or for Treatment of Recurrent Triple-Negative Breast Cancer
Brief Summary: This partially randomized phase I/II trial studies the side effects and the best dose of cediranib maleate and olaparib and to see how well they work compared to olaparib alone in treating patients with ovarian, fallopian tube, peritoneal, or triple-negative breast cancer that has returned after a period of improvement (recurrent). Cediranib maleate may help keep cancer cells from growing by affecting their blood supply. Olaparib may stop cancer cells from growing abnormally. The combination of cediranib maleate and olaparib may be safe, tolerable and/or effective in treating patients with recurrent ovarian, fallopian tube, or peritoneal cancer or recurrent triple-negative breast cancer.


Options:
A: Arm Label: Arm I (placebo, paclitaxel, carboplatin); Type: ACTIVE_COMPARATOR; Interventions: Drug: Carboplatin, Other: Laboratory Biomarker Analysis, Drug: Paclitaxel, Other: Placebo, Other: Quality-of-Life Assessment | Arm Label: Arm II (placebo, paclitaxel, carboplatin, bevacizumab); Type: EXPERIMENTAL; Interventions: Biological: Bevacizumab, Drug: Carboplatin, Other: Laboratory Biomarker Analysis, Drug: Paclitaxel, Other: Placebo, Other: Quality-of-Life Assessment | Arm Label: Arm III (paclitaxel, carboplatin, bevacizumab); Type: EXPERIMENTAL; Interventions: Biological: Bevacizumab, Drug: Carboplatin, Other: Laboratory Biomarker Analysis, Drug: Paclitaxel, Other: Quality-of-Life Assessment | Intervention Type: BIOLOGICAL; Name: Bevacizumab; Assigned to Arm(s): Arm II (placebo, paclitaxel, carboplatin, bevacizumab), Arm III (paclitaxel, carboplatin, bevacizumab) | Intervention Type: DRUG; Name: Carboplatin; Assigned to Arm(s): Arm I (placebo, paclitaxel, carboplatin), Arm II (placebo, paclitaxel, carboplatin, bevacizumab), Arm III (paclitaxel, carboplatin, bevacizumab) | Intervention Type: OTHER; Name: Laboratory Biomarker Analysis; Assigned to Arm(s): Arm I (placebo, paclitaxel, carboplatin), Arm II (placebo, paclitaxel, carboplatin, bevacizumab), Arm III (paclitaxel, carboplatin, bevacizumab) | Intervention Type: DRUG; Name: Paclitaxel; Assigned to Arm(s): Arm I (placebo, paclitaxel, carboplatin), Arm II (placebo, paclitaxel, carboplatin, bevacizumab), Arm III (paclitaxel, carboplatin, bevacizumab) | Intervention Type: OTHER; Name: Placebo; Assigned to Arm(s): Arm I (placebo, paclitaxel, carboplatin), Arm II (placebo, paclitaxel, carboplatin, bevacizumab) | Intervention Type: OTHER; Name: Quality-of-Life Assessment; Assigned to Arm(s): Arm I (placebo, paclitaxel, carboplatin), Arm II (placebo, paclitaxel, carboplatin, bevacizumab), Arm III (paclitaxel, carboplatin, bevacizumab)
B: Arm Label: Arm 1; Type: ACTIVE_COMPARATOR; Interventions: Drug: Carboplatin, Drug: Paclitaxel, Drug: Niraparib | Arm Label: Arm 2; Type: ACTIVE_COMPARATOR; Interventions: Drug: Carboplatin, Drug: Paclitaxel, Drug: Bevacizumab, Drug: Niraparib | Intervention Type: DRUG; Name: Carboplatin; Assigned to Arm(s): Arm 1, Arm 2 | Intervention Type: DRUG; Name: Paclitaxel; Assigned to Arm(s): Arm 1, Arm 2 | Intervention Type: DRUG; Name: Bevacizumab; Assigned to Arm(s): Arm 2 | Intervention Type: DRUG; Name: Niraparib; Assigned to Arm(s): Arm 1, Arm 2
C: Arm Label: Arm I (cediranib maleate and olaparib); Type: EXPERIMENTAL; Interventions: Procedure: Biopsy Procedure, Procedure: Biospecimen Collection, Drug: Cediranib Maleate, Procedure: Computed Tomography, Procedure: Echocardiography Test, Procedure: Magnetic Resonance Imaging, Procedure: Multigated Acquisition Scan, Drug: Olaparib | Arm Label: Arm II (olaparib); Type: ACTIVE_COMPARATOR; Interventions: Procedure: Biopsy Procedure, Procedure: Biospecimen Collection, Procedure: Computed Tomography, Procedure: Echocardiography Test, Procedure: Magnetic Resonance Imaging, Procedure: Multigated Acquisition Scan, Drug: Olaparib | Intervention Type: PROCEDURE; Name: Biopsy Procedure; Assigned to Arm(s): Arm I (cediranib maleate and olaparib), Arm II (olaparib) | Intervention Type: PROCEDURE; Name: Biospecimen Collection; Assigned to Arm(s): Arm I (cediranib maleate and olaparib), Arm II (olaparib) | Intervention Type: DRUG; Name: Cediranib Maleate; Assigned to Arm(s): Arm I (cediranib maleate and olaparib) | Intervention Type: PROCEDURE; Name: Computed Tomography; Assigned to Arm(s): Arm I (cediranib maleate and olaparib), Arm II (olaparib) | Intervention Type: PROCEDURE; Name: Echocardiography Test; Assigned to Arm(s): Arm I (cediranib maleate and olaparib), Arm II (olaparib) | Intervention Type: PROCEDURE; Name: Magnetic Resonance Imaging; Assigned to Arm(s): Arm I (cediranib maleate and olaparib), Arm II (olaparib) | Intervention Type: PROCEDURE; Name: Multigated Acquisition Scan; Assigned to Arm(s): Arm I (cediranib maleate and olaparib), Arm II (olaparib) | Intervention Type: DRUG; Name: Olaparib; Assigned to Arm(s): Arm I (cediranib maleate and olaparib), Arm II (olaparib)
D: Arm Label: Placebo; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo, Drug: aflibercept (ziv-aflibercept, AVE0005, VEGF trap, ZALTRAP®) | Arm Label: Aflibercept; Type: EXPERIMENTAL; Interventions: Drug: aflibercept (ziv-aflibercept, AVE0005, VEGF trap, ZALTRAP®) | Intervention Type: DRUG; Name: aflibercept (ziv-aflibercept, AVE0005, VEGF trap, ZALTRAP®); Assigned to Arm(s): Aflibercept | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): Placebo | Intervention Type: DRUG; Name: aflibercept (ziv-aflibercept, AVE0005, VEGF trap, ZALTRAP®); Assigned to Arm(s): Aflibercept, Placebo

Answer: C